
MGTX Stock Forecast & Price Target
MGTX Analyst Ratings
Bulls say
MeiraGTx Holdings PLC is expanding its financial runway into 2027, supported by the anticipated closing of the Hologen deal, indicating strong liquidity and operational stability. The company is focused on innovative one-time functional cures in ophthalmology, with Phase II trial results showing positive outcomes, including statistically significant improvements in visual acuity and patient-reported outcomes. Additionally, with a Biologics License Application (BLA) filing expected in 2026 and promising data from pediatric cases, MeiraGTx demonstrates potential for strong future growth in the gene therapy market.
Bears say
MeiraGTx Holdings PLC faces significant risks related to regulatory approval for its pipeline products, as any delays or complexity in the approval process could lead to substantial downward revisions in risk-adjusted projections and price targets. The company's financial performance is concerning, as it reported a net loss of $148 million, translating to an EPS of ($2.12), which exceeds prior loss estimates. Additionally, challenges related to the pricing of its gene therapies in comparison to existing orphan drugs and a higher likelihood of manufacturing setbacks present further uncertainties that could negatively impact financial forecasts.
This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.
MGTX Analyst Forecast & Price Prediction
Start investing in MGTX
Order type
Buy in
Order amount
Est. shares
0 shares